Hey everybody, we made it to #50! In this episode, I chat with Nathan Weinstein from Aegis Capital about Acasti Pharma. We discuss the omega-3 space and Acasti's EPA/DHA formulation called CaPre. Acasti is seeking the approval of CaPre for the indication of severe hypertriglyceridemia and has two pivotal catalysts at the end of the year, which will be massive movers for the stock. Amarin's upcoming catalysts are also likely to affect them. Check out the whole video for more details! Relevant links: https://www.acastipharma.com/en/investors/company-information/presentations https://www.aegiscapcorp.com/service/nathan-weinstein/ this is not investment advice breakingbiotech #acst #amrn Support Breaking Biotech by donating to their Tip Jar: https://tips.pinecast.com/jar/breaking-biotech